Osteonecrosis is a frequent complication after treatment for childhood leukemia and other steroid-based therapies. The success rate of core decompression surgery is limited. Therefore, we evaluated relevant biological characteristics of human multipotent mesenchymal stromal cells (MSCs) in vitro. MSCs cultured under low-oxygen tensions showed decreased proliferation and differentiation into bone. However, these MSCs secreted significant amounts of vascular endothelial-derived factor in the presence of interferon-c. These in vitro results with potential effects on neovascularization and bone regeneration as well as findings in animal models prompted us to treat five patients with steroid-induced osteonecrosis of the femur by core decompression surgery and instillation of expanded autologous MSCs. Within 3 weeks of culture, sufficient numbers of MSCs were generated using animal protein-free culture conditions. No chromosomal aberrations were detected by matrix-based comparative genomic hybridization. Application of MSCs during core decompression was feasible and safe. Median follow-up is 16 months and the patients in this pilot study reported clinical improvement. Formation of mineralized bone in the osteonecrotic cavity was proven by computed tomography. Taken together, MSCs display biological properties that may add to the efficiency of surgical treatment in osteonecrosis and should be evaluated in larger patient cohorts.
Introduction
Osteonecrosis in pediatric patients is frequently caused by steroid-based therapy of hematological malignancies. 1 Furthermore, alterations of blood rheology, for example, in sickle-cell anemia or coagulopathies, render children susceptible to avascular necrosis (AVN) of the bone. 2 Predominantly femora are affected with distal epiphyseal lesions being more frequent than proximal defects. The incidence of AVN in children under the age of 10 years is below 0.2% after treatment in the acute lymphoblastic leukemia (ALL)-Berlin-Frankfurt-Mü nster (BFM) protocol 95, however, 16% of the teenagers older than 15 years in the same protocol are affected by AVN. In other studies, the risk of bone morbidity has been found to be even higher. 3 Thus, AVN is a frequent complication of steroid-based therapy for hematological malignancies. Similarly, juvenile idiopathic arthritis or other autoimmune diseases in children may lead to AVN, when steroids are added to the treatment regimen. 4 Radiological evaluation of AVN is complicated by the absence of a consensus scoring system. 5 Often the localization warrants adaptations of staging systems as it has been proposed for the knee, the most frequent site of steroid-induced osteonecrosis in children with hematological malignancies. 6, 7 Correlation of imaging results with clinical symptoms such as pain, reduced mobility or immobilization is even more difficult in children. 8 Current treatment strategies aim primarily at elimination of pain, restoration of function and prevention of disease progression. Conservative measures are limited to immobilization and physiological rehabilitation, which is often complicated in children due to compliance problems. 9 Surgical measures include core decompression and ultimately prosthetic replacement of the femoral head or the knee. The outcome after core decompression is very variable and often dependent on risk factors, localization and surgical accessibility. [10] [11] [12] To improve the efficacy of core decompression, healthy bone marrow or bone marrow mononuclear cells from an aspirate at a distant site have been instilled during the intervention. [13] [14] [15] This approach is very promising as histopathological findings clearly indicated that the number of osteogenic cells is significantly reduced in border zones of steroid-associated AVN. 16 The most potent osteogenic cells in the bone marrow known to date are multipotent mesenchymal stromal cells (MSCs). [17] [18] [19] Recent analyses of this population in the marginal zone of steroid-induced AVN also showed a significant reduction in number, viability and plasticity. 20 Preclinical animal models have already shown the beneficial effect of MSCs placed in bone defects caused by various pathophysiological conditions. [21] [22] [23] Successful systemic application of MSC in children for metabolic bone disorders such as osteogenesis imperfecta prompted us to explore biological properties of MSCs with regard to AVN. 24, 25 In particular, we sought for secreted factors modulating the hypoxic and inflammatory environment, which seems equally important as transdifferentiation of MSCs. 26 On the one hand angiogenic factors, for example, vascular endothelialderived growth factor (VEGF), are of crucial importance for tissue regeneration at the site of AVN. On the other hand, osteogenic proteins, including the insulin-like growth factors (IGFs) are of high relevance.
On the basis of the in vitro findings presented here and the experience with animal models, we developed a procedure to harvest 10-ml bone marrow from the hip before the core decompression surgery and expand MSCs within 3 weeks by culture in an animal serum-free medium. These cells were then deposited at the site of the AVN during conventional core decompression. Here, we report promising biological properties of MSCs in AVN and their application in five pediatric patients with a maximum follow-up of 22 months. 
Patients, materials and methods

Patients
Bone marrow harvest
After local disinfection and anesthesia, 10 ml heparinized bone marrow was aspirated from the posterior iliac spine. Subsequently, red blood cell lysis was performed at room temperature by ammonium chloride lysis (8.29 g ammonium chloride, 1 g potassium hydrogencarbonate, 37 mg Na 2 EDTA Á H 2 O and 1000 ml ddH 2 O). After a washing step with Hank's buffered salt solution, cells were resuspended in 50 ml of low glucose Dulbecco's modified Eagle's medium (DMEM; Cambrex, Verviers, Belgium) supplemented with 5% (v/v) fresh frozen plasma (blood donor center Tü bingen, Germany), 5% (v/v) platelet lysate (starting concentration 10 8 platelets per ml plasma; blood donor center Tü bingen) and 1 mM glutamine (Cambrex). Cells were cultured for 48 h at 37 1C under 10% CO 2 and nonadherent cells were removed. Adherent cells were detached using recombinant trypsin (TrypLE; Gibco, Paisley, UK) and passaged when 80% confluency was reached. MSCs were replated at a density of 200 cells per cm 2 in 175 cm 2 flasks (Corning, Corning, NY, USA). After three passages culture was discontinued, MSCs were harvested, washed and brought up to 3 ml in physiological NaCl solution containing 0.1% human albumin (Octapharma, Langenfeld, Germany).
Immunophenotyping
Flow cytometric analysis was performed on a FACSCalibur (Becton Dickinson, Heidelberg, Germany) and data were analyzed by the CellQuest software (Becton Dickinson). AntiIgG1-FITC (clone MOPC-31C), anti-IgG1-PE (clone G18-145), anti CD45-FITC (HI30), anti-CD34-PE (563), anti-CD73-PE (A02), anti-HLA-DR-FITC (TÜ 36) and anti-HLA-ABC-PE (G46-2.6) monoclonal antibodies were obtained from Becton Dickinson; in addition anti-CD105-FITC (N1-3A1) was purchased from Ancell (Bayport, MN, USA).
Cytokine assays Interferon-g. Supernatants of MSCs cultured in 21% O 2 and in 1% O 2 , respectively, were collected after 12 h, 1 day, 2 days, 3 days and 4 days. Levels of VEGFs were measured using the interferon-g (IFNg) enzyme-linked immunosorbent assay (ELISA) kits (CytoSet, Biosource, Nivelles, Belgium) according to the manufacturer's instructions. 
IGFs and IGFBPs. IGF-I, IGF-II, IGF-binding protein (IGFBP)-
Array-based comparative genomic hybridization
Array-(or matrix-) comparative genomic hybridization (CGH) 27 was carried out as previously described. 28 Selection of genomic clones, isolation of bacterial artificial chromosome (BAC) DNA, performance of Degenerate Oligonucleotid Primer-PCR, preparation of microarrays, labeling, hybridization and washing procedures were performed as outlined. Raw data processing and normalization was performed as previously reported providing log 2 ratios of spot intensities. 29 The chromosomal mapping information is based on the University of California at Santa Cruz genome database (March 2006) and the March 2006 (hg18) assembly (NCBI Build 36.1) of the International Human Genome Sequencing Consortium. All clones from a total of 11 samples were subjected to preprocessing that included elimination of clones with incomplete mapping information or missing data in more than 20% of cases. This resulted in 7980 clones evaluable for further analysis. In the next step, genomic events were assigned. The median of all median absolute deviations across all chromosomes is taken to estimate the sample experimental variability (genomic 'standard deviation', SD g ). Gains and losses are defined by log 2 ratios larger than three times SD g or smaller than À3 times SD g , respectively.
Differentiation assay
MSCs were induced toward the osteogenic lineage as potency assay. MSCs were seeded in bone induction medium with LG-DMEM (Gibco) containing 10% fetal calf serum (FCS; Hyclone, Logan, UT, USA), 10 4 IU/ml penicillin, 10 mg/ml streptomycin, glutamine (2 mM), supplemented with dexamethasone (10 nM), L-ascorbic acid-2-phosphate (0.1 mM), b-glycerol phosphate (5 mM) (Sigma, Munich, Germany) and bone morphogenetic protein-2 (BMP-2; 100 ng/ml) (Tebu-Bio, Magenta, Italy). After 2 weeks, differentiated MSCs and controls were stained with aequous 0.5% (v/v) alizarin Red-S (Sigma) and washed with phosphate-buffered saline (PBS) with 10% (v/v) cetylpiridinium (Sigma).
Alkaline phosphatase assay
Starting with 5 Â 10 2 MSCs per cavity of a 96-well plate, osteogenic differentiation was induced 24 h after seeding as described above. Following 14 d of differentiation, the medium was removed and the cells were washed once with 10 mM PBS. Lysis buffer (100 ml) (0.1% saponin (Sigma) in 100 mM sodium bicarbonate/carbonate buffer) was added to each well and incubated for 15 min at room temperature. An equal volume of alkaline phosphatase substrate (5 mM p-nitrophenyl phosphate (Vector Laboratories, Orton Southgate, Peterborough, UK) in 100 mM sodium bicarbonate/carbonate buffer) was combined with lysis solution in a separate 96-well plate and incubated for 10 min at 37 1C. Measuring of optical density was performed in a plate assay reader (Milenia Kinetic Analyzer, DPC, Los Angeles, CA, USA) at 405-650 nm.
MSC release criteria
Release criteria included culture for less than 4 weeks, viability 490%, expression of CD73 and CD105 by more than 90% of the cells as assessed by flow cytometry. These culture conditions had been shown to yield MSCs maintaining plasticity. Sterility tests were performed at start of the culture and during the last passage 1 week before administration. All cell-culture steps were performed in the in-house good manufacturing practice (GMP) facility.
Surgical procedure
The patient was placed on a radiolucent table with the image intensifier placed over the AVN. After sterile draping of the leg, the exact location of the necrosis was identified with the help of an image intensifier. The location of the necrosis on the radiographs was correlated with the preoperative magnetic resonance images. Through a stab incision, a 3.2 mm drill was approached to the necrotic area under radiographic control and correct orientation of the drill direction was checked at least in two planes. Now the necrotic focus was perforated with multiple drill holes in a fan-like fashion. Care was taken not to violate the subchondral and chondral area. Sometimes necrotic regions in the medial and the lateral condyle of one knee have to be addressed. Then up to 5 ml of the suspension containing autologous MSCs were injected through the drill holes. The correct positioning of the canula was monitored and verified radiologically. Reflux of the cell suspension was prevented by closure of the outer part of the drill holes with fibrin glue.
Results
Secretion of IGFs and IGFBPs by MSCs in a hypoxic environment
AVN represents an area of absent blood perfusion and consequently low supplies of nutrients and oxygen. Therefore, we cultivated MSCs under oxygen tensions of 1%. Expectedly, these cells showed slowed proliferation and differentiation into bone (data not shown). Although several studies have investigated the role of BMPs secreted by MSCs, 30 the role of other factors have not been studied to the same extent. We analyzed the protein levels of IGFs and their binding proteins (IGFBPs), because these proteins are known to be intimately involved in regulation of bone metabolism. We found that MSCs grown under low-oxygen conditions secreted significant amounts of IGF-I and IGF-II, however with distinct kinetics (Figure 1) . Although IGF-I decreased over time, IGF-II was accumulated in the supernatant of MSCs. There were only minor kinetic differences in the cultures kept under 21 and 1%. IGFBP-2 and -3 were expressed by MSCs under high-and low-oxygen conditions. In contrast to IGF-I, the concentrations of IGFBPs increased over time. This shows that key factors of the IGF network relevant for bone metabolism are present at the protein level in MSC cultures under high and under low-oxygen tensions.
Hypoxia and IFNg synergistically induce secretion of VEGF by MSC
On the basis of the observation that osteogenic differentiation of MSCs is hampered under hypoxic conditions, we asked if MSCs secrete factors that might improve vascularization of the necrotic area in a clinical setting. Therefore, we analyzed the concentrations of VEGF in the supernatant of MSCs (Figure 2 ). We observed an accumulation of minor amounts of VEGF under 21% oxygen over the course of 72 h. Surprisingly, in our hands MSCs did not produce significant amounts of VEGF even under hypoxic culture conditions with oxygen levels as low as 1%. 31 The osteonecrotic border zone represents an inflammatory environment and we thus investigated the effect of IFNg as one of the most abundant inflammatory cytokines in this situation. Interestingly, MSCs produced strongly elevated levels of VEGF under hypoxic conditions in the presence of IFNg, whereas neither hypoxia nor IFNg alone could achieve similar effects. This indicates that MSCs are capable to produce vasculogenic cytokines in an environment resembling the border zone of AVN.
Chromosomal stability of MSC in culture under 21% oxygen
On the basis of these interesting findings and reports in the literature, we began further preclinical testing of MSCs before application in AVN (Figure 3) . In the light of recent reports on the malignant transformation of MSCs, we analyzed chromosomal stability of MSCs under clinical expansion conditions with the use of human platelet lysate and plasma. We did not detect chromosomal alterations using high-resolution matrix-based CGH in the three independent samples tested during shortand long-term cultures. Even after prolonged culture under 21% oxygen, there were no aberrations detectable after 12 weeks. Nevertheless, we aimed at a culture period of 3 weeks in clinical application for AVN, never exceeding 4 weeks.
Osteogenic potential of MSCs from patients with avascular osteonecrosis
First, we ensured that MSCs from patients with AVN are capable to differentiate along the osteogenic lineage. To this end, excess material from diagnostic bone marrow aspirates drawn from the iliac crest of patients with ALL, and osteonecrosis was obtained and MSCs were expanded as described earlier. 32 Importantly, the cells were cultured under GMP conditions without the use of animal proteins employing platelet lysate and human fresh frozen plasma as source for growth factors. MSCs grown under these conditions were shown to be able to differentiate into osteoblasts with high efficiency using the alizarin red stain for calcium phosphate precipitates (Figures 4a). Addition of IFNg had no effect on osteogenic differentiation, neither under atmospheric nor under reduced oxygen tension. In addition, alkaline phosphatase activity was readily induced in these cells during conventional differentiation assays. 
Patient characteristics
On the basis of the promising properties of MSCs for avascular osteonecrosis in vitro and in vivo observations as mentioned in the introduction and discussed below, we sought to obtain initial feasibility and safety data on the clinical use of autologous MSCs during core decompression surgery in patients with AVN following high-dose steroid treatment for autoimmune or hematological disorders. We recruited five patients as detailed in Table 1 . MSCs could be expanded from all five patients using human platelet lysate and plasma. The total volume of packed MSCs exceeded the estimated volume of the AVN in all cases, thus sufficient numbers of MSCs were obtained in the set time frame of 3 weeks.
Radiological findings and follow-up of the patients
The surgical procedure is exemplified by imaging of patient 1 ( Figure 5 ). The osteonecrotic cavity is identified by magnetic resonance imaging (MRI) and intraoperatively by X-ray. After core decompression, MSCs are placed in situ through the canula depicted in Figure 5b . Median follow-up is 16 months (11 to 24 months) and included MRI and conventional radiography (Figure 5c) . None of the patients suffered intraoperative complications. Most importantly, no infectious events were observed, neither during the culture period nor after surgery. Thus, application of MSCs in this small patient group was feasible and safe. Clinically, none of the patients deteriorated.
Pain was reduced in all of the patients and daily activity improved consequently. The statistical significance of these observations can only be evaluated in larger patient cohorts.
Discussion
MSCs have been used in numerous clinical applications. Predominantly immunomodulatory properties have been exploited in these instances. 26, [33] [34] [35] In other transplant settings, MSCs were used for improved engraftment and prevention of rejection. [34] [35] [36] In these applications, a long-term engraftment has been documented by some groups, but not by others. [37] [38] [39] [40] It is a matter of debate, whether MSCs may differentiate into the tissues of interest, although this has been shown in various animal models. 23, 41, 42 In some studies, the beneficial effect of MSCs rather was attributed to the secretion of cytokines and growth factors at the site of injury. 43, 44 Obviously, for the use of MSCs in regenerative medicine, a sustained engraftment is Figure 4 Mesenchymal stromal cells (MSCs) can be expanded from individuals with osteonecrosis from a bone marrow biopsy at a distant site in platelet lysate-supplemented culture media. These cells can readily be induced to an osteogenic phenotype resulting in deposition of calcium phosphate precipitates as shown in micrographs after alizarin red stain (a) and produce alkaline phosphatase (b) (n ¼ 5). Interferon-g (IFNg) had no significant effect on osteogenic differentiation (n ¼ 3).
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Biological and clinical properties of MSC in AVN I Müller et al desirable. For bone formation, this has been shown in the pioneer study by Horwitz et al. 24, 25 as well as by intrauterine transplantation of MSCs in a fetus with osteogenesis imperfecta. On the basis of these observations, we hypothesized that bone repair may be even more efficient in the case of focal lesions, when MSCs can be applied directly and issues of extravasation, migration and homing can be reduced. In fact, the osteonecrosis model takes advantage of both mechanisms, secretion of tissuerepair modulating factors as well as osteogenic differentiation.
Osteonecrotic lesions are bradytrophic areas with low concentrations of oxygen and nutrients. To evaluate these environmental effects on MSCs after deposition by surgical intervention, we tested low-oxygen culture conditions for MSCs. Interestingly, VEGFs and IGFBPs were elevated. These factors are antiapoptotic in many assays and involved in neovascularization. 45 It is noteworthy, that MSCs grow in culture media with low glucose content and thus are adapted to limited nutrient supply at the time when they are injected into the necrotic Abbreviations: ALL, acute lymphoblastic leukemia; AVN, avascular necrosis; MSCs, mesenchymal stromal cells; T-NHL, T-lymphoblastic nonHodgkin lymphoma.
lesion. In addition, we found that MSCs secrete IGFs, which are important regulators of bone formation. [46] [47] [48] MSCs may secrete the above factors to facilitate nutrition by diffusion and subsequently to induce vascularization of the necrotic area. Due to the fact that none of the patients had to undergo implantation of an endoprothesis, we have no histological analysis of the necrosis. Although the number of patient treated here is small, safety and feasibility have been proven. We have not observed complications like infections that would have destroyed the affected joint in this situation. Stringent quality controls are implemented to ensure sterility of the expansion process at each step.
Tumorigenicity of culture-expanded MSCs has been demonstrated lately. 49, 50 Therefore, we carefully analyzed our new expansion conditions using platelet lysate. Limiting the duration of expansion to 3 weeks in most cases and not exceeding 4 weeks provided a safe product in these patients. Chromosomal abnormalities were absent and no phenotypic changes have been observed either by microscopy or by flow cytometry. This is the first report of clinical application of human MSCs expanded without FCS and porcine trypsin. This procedure is compliant with current regulations and requirements for GMP-conform expansion of human cells.
Taken together, we demonstrated biological properties of MSCs in vitro that may prove beneficial for patients with osteonecrosis. This patient series with osteonecrosis treated by core decompression surgery and concomitant application of autologous MSCs proved safety and feasibility of the approach. A phase I/II trial is required to address these aspects more conclusively. Beneficial effects need to be demonstrated in larger patient numbers.
